Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCI699 proof-of-concept study in Cushing's disease
2010-022403-22Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osilodrostat in Corticotropin adenoma (ACTHoma), sponsored by Novartis. Primary endpoint: Effect of 10 weeks of LCI699 on urinary free cortisol. Started Sep 2011; status: completed.
02
Drugs
osilodrostat
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2010-022403-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022403-22.